咪唑并[1,2- a ]吡嗪,咪唑并[1,5- a ]喹喔啉和吡唑并[1,5- a ]喹喔啉衍生物作为IKK1和IKK2抑制剂
摘要:
转录核因子NF-κB在慢性和急性炎症性疾病中起关键作用。在抑制NF-κB的几种不同策略中,IKK抑制剂的开发似乎是制药业考虑的最有效方法之一。在以前的研究中,在一系列咪唑并[1,2- a ]喹喔啉衍生物中突出了两种潜在的IKK2抑制剂。为了增强该活性,我们在此提出基于咪唑并[1,2- a ]吡嗪,咪唑并[1,5- a ]喹喔啉或吡唑并[1,5- a ]喹喔啉的二十一种新化合物的合成。结构。还测试了它们抑制IKK1和IKK2活性的潜力。
Synthesis of imidazo[1,5-a]quinoxalin-4(5H)-one template via a novel intramolecular cyclization process
作者:Derek Norris、Ping Chen、Joel C Barrish、Jagabandhu Das、Robert Moquin、Bang-Chi Chen、Peng Guo
DOI:10.1016/s0040-4039(01)00698-0
日期:2001.6
A novel, efficient, and regiospecific method for the construction of the imidazo[1,5-a]quinoxalin-4(5H)-one template is described. The key reaction involves an intramolecularcyclization process and provides the desired products in excellent yield.
描述了一种新颖,有效且针对区域的方法,用于构建咪唑并[1,5 - a ]喹喔啉-4(5 H)-one模板。关键反应涉及分子内环化过程,并以优异的产率提供所需的产物。
In vitro and in vivo anti-tumoral activities of imidazo[1,2-a]quinoxaline, imidazo[1,5-a]quinoxaline, and pyrazolo[1,5-a]quinoxaline derivatives
Imidazoquinoxaline and pyrazoloquinoxaline derivatives, analogues of imiquimod, were synthesized, and their in vitro cytotoxic and pharmacodynamic activities were evaluated. In vitro cytotoxicity studies were assessed against melanoma (A375, M4Be, RPMI-7591), colon (LS174T), breast (MCF7), and lymphoma (Raji) human cancer cell lines. In vivo studies were carried out in M4Be xenografted athymic mice. EAPB0103, EAPB0201, EAPB0202, and EAPB0203 showed significant in vitro activities against A375 compared to fotemustine and imiquimod used as references. These compounds were 6-110 and 2-45 times more active than fotemustine and imiquimod, respectively. EAPB0203 bearing phenethyl as substituent at position 1 and methylamine at position 4 showed the highest activity. EAPB0203 has also a more potent cytotoxic activity than imiquimod and fotemustine in M4Be and RPMI-7591 and interesting cytotoxic activity in other tumor cell lines tested. In vivo, EAPB0203 treatment schedules caused a significant decrease in tumor size compared to vehicle control and fotemustine treatments. (c) 2008 Elsevier Ltd. All rights reserved.